GENFIT focuses on Acute on-chronic Liver Failure (ACLF) and associated conditions such as acute decompensation (AD) and hepatic encephalopathy (HE), developing therapeutic assets with complementary mechanisms of action, and also targets other serious diseases such as cholangiocarcinoma (CCA), urea cycle disorders (UCD) and organic acidemia (OA). In 2021, Ipsen became one of GENFIT's largest shareholders, acquiring an 8% stake in the Company's capital.
Cyborg Score Rationale
As of December 31, 2025, the Company's cash and cash equivalents amounted to €101.1 million. GENFIT expects that its existing cash and cash equivalents will enable the Company to fund operating expenses and capital expenditure requirements beyond the end of 2028. G1090N demonstrated a favorable Phase 1 safety profile and strong anti-inflammatory activity.
Top Insights
Ipsen's strong performance with Iqirvo® generated >$200M net sales in year one, triggering GENFIT's milestone payment.
Cash position increased to €101.1 million by year-end 2025, supported by €26.55 million milestone received upon pricing approval of Iqirvo® in Italy.
Lead ACLF candidate G1090N demonstrated favorable safety profile with strong anti-inflammatory activity, positioning it as promising for acute decompensation.
GENFIT achieved B Corp certification in 2025 and operates across France, Switzerland, and the USA.
Named Competitors
Obeticholic acid — PBC treatment (competitor to Iqirvo®)
Various NASH/MASH programs — Competing in metabolic liver disease diagnostics and therapeutics
GLP-1 therapies — Emerging treatments for metabolic liver conditions
Recent Developments
(February 2026) Cash position of €101.1 million reported as of December 31, 2025.